Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.51 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.51 |
| ▸ | PDE4A | P27815 | 14/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 14/20 | 0.51 |
| ▸ | HTR2B | P41595 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4428840 | 0.87 | PDE4B (0.62) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825653 | 0.86 | PDE4B (0.53) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5189259 | 0.84 | PDE4B (0.51) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5191578 | 0.82 | PDE4A (0.45) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5277127 | 0.80 | PDE4B (0.47) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537498 | 0.78 | PDE4B (0.80) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL5189328 | 0.76 | PDE4B (0.40) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL25205204 | 0.76 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL825619 | 0.76 | PDE4B (0.69) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL6025567 | 0.75 | PDE4B (0.64) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1729764-A4 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORP (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1729764-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2005094218-A2 | METHODS OF USING AND COMPOSITIONS COMPRISING SELECTIVE CYTOKINE INHIBITORY DRUGS FOR THE TREATMENT AND MANAGEMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM | CELGENE CORPORATION (US) | 2005-10-13 | — | — | WO | disclosed |